Immatics (IMTX) Income from Non-Controlling Interests (2019 - 2021)
Immatics (IMTX) reported Income from Non-Controlling Interests of -$33.6 million for Q2 2021, down 10692.4% on a YoY basis from N/an in Q2 2020, and down 10692.4% sequentially from -$311713.2 in Q2 2020.
Immatics (IMTX) Income from Non-Controlling Interests (2019 - 2021) Analysis & Trends
Immatics (IMTX) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$33.6 million in Q2 2021.
- For the quarter ending Q2 2021, Income from Non-Controlling Interests fell 10692.4% year-over-year to -$33.6 million; the trailing twelve-month figure through Mar 2024 stood at -$311713.2 (changed N/A YoY), and the FY2020 full-year result was -$635968.0, up 38.01% from the prior year.
- Income from Non-Controlling Interests slipped to -$33.6 million in Q2 2021, from -$311713.2 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$249049.7 in Q4 2019 to a low of -$33.6 million in Q2 2021.
- A 3-year average of -$5.8 million and a median of -$297007.3 in 2019 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests dropped 19.58% in 2020 and plunged 10692.4% in 2021, its largest moves.
- Tracing IMTX's Income from Non-Controlling Interests over 3 years: stood at -$249049.7 in 2019, then decreased by 25.16% to -$311713.2 in 2020, then sank by 10692.4% to -$33.6 million in 2021.
- Business Quant data shows IMTX's Income from Non-Controlling Interests at -$33.6 million in Q2 2021, -$311713.2 in Q2 2020, and -$302479.3 in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Immatics | 1.11 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -33.64 Mn |
| Jun 30, 2020 | -311,713.22 |
| Mar 31, 2020 | -302,479.29 |
| Dec 31, 2019 | -249,049.73 |
| Sep 30, 2019 | -291,535.27 |
| Jun 30, 2019 | -260,684.27 |